The Times Australia
The Times Australia
.

Does Australia really take too long to approve medicines, as the US says?

  • Written by Nial Wheate, Professor, School of Natural Sciences, Macquarie University




Australia’s drug approval system is under fire, with critics in the United States[1] claiming it is too slow to approve life-saving medicines.

Australia’s Therapeutic Goods Administration balances speed with a rigorous assessment of safety, efficacy and cost-effectiveness.

So does Australia really lag behind the US Food and Drug Administration[2]? And do we need to change how we approve medicines?

The drug development pipeline

Drug development usually begins when something new is discovered about a disease. This usually involves identifying either a change in an important protein or finding a new protein involved in the disease.

When scientists know the shape of the protein, they can design a drug that can block or activate it.

Scientists will then undertake laboratory, petri dish-type, experiments to see if the drug works on the protein in the way they designed. If it passes those tests, they will then move onto animal testing and formulation.

Formulation is the step where scientists decide what form the medicine will take, such as a tablet, injection or patch. There are more than 150 different pharmaceutical dosage forms[3] to choose from.

The final steps are human testing. This requires the completion of three types of clinical trials[4]. Each seeks to answer different specific questions about the drug:

  • Phase I trials: is the drug safe? What are its side effects?
  • Phase II trials: does the drug work?
  • Phase III trials: is the drug better than currently available medicines?

At the end of the trials, a company can apply to the Therapeutic Goods Administration (TGA) for approval to market and sell the drug.

Getting a drug to market is time-consuming and costly. It takes around 15 years[5] from the initial concept and design to government approval and costs more than A$3.5 billion[6].

But the failure rate is high: more than 90% of drugs[7] that undergo development never gain government approval.

How are drugs approved in Australia?

The decision to approve new medicines for sale in Australia is made based on safety and efficacy evidence provided by the sponsoring company.

Once approved, the drug is added to the Australian Register of Therapeutic Goods[8].

Listing a medicine on the Pharmaceutical Benefits Scheme[9] (PBS) is a separate process from approval, and is based on financial considerations and a cost-benefit analysis, rather than safety and efficacy.

The TGA typically takes 240 to 260[10] working days (around a full calendar year) from receiving a new medicine application to an approval decision. This is longer than it takes the US Food and Drug Administration (FDA) – 180 to 300 days[11].

Where there is a pressing need, the approval process can be faster. The first COVID treatment was approved in Australia just two weeks[12] after it was submitted for consideration.

Then why do Americans often get medicines first?

There can be several reasons why a drug approval can be delayed in Australia when it has already been approved overseas.

First, with a population of 27 million out of 8 billion world-wide, Australia is a relatively small market. So it is not always a high priority for companies to apply for approval here. Regions with large populations such as China, India and Europe are a bigger focus for companies. This can therefore delay when they submit to Australia.

Other reasons for delays can be that the TGA requires additional safety or efficacy evidence other regions did not request, or because new information about the drug has come to light since the drug was approved overseas.

What about delays getting drugs onto the PBS?

When a drug is listed on the PBS, Australians can access the medicine for $31.60 (or $7.70 concession) instead of the cost of a private prescription which might be hundreds or even thousands of dollars.

The time it takes for medicines to be approved on the PBS has also been a focus of criticism.

The Pharmaceutical Benefits Advisory Committee (PBAC), which makes PBS listing recommendations to the Federal Minister of Health, only sits three to six times[13] per year.

US Chamber of Commerce vice president John Murphy claims the PBAC takes, on average, 32 months[14] to make a recommendation about listing a drug after an application has been submitted.

Once a recommendation is made, the minister usually takes[15] a minimum of five months to make a final decision.

Read more: Australia’s PBS means consumers pay less for expensive medicines. Here’s how this system works[16]

To speed up the process, the TGA does allow parallel applications[17] for drug approval and PBS listing.

The time taken to make a PBS listing decision is reasonable, given the scheme’s overall cost. In 2023–24, the total cost of the PBS to the government was $17.7 billion[18]. So a decision to list can’t be made lightly.

So should Australia change how it approves medicines?

Criticising the time it takes to get regulatory approvals appears to be part of a wider plan of attack by the US government. It is putting pressure on Australia to open its market to higher prices for medicines made by US pharmaceutical companies.

Australia has a world-class regulatory agency in the TGA which ensures medicines that are approved are both safe and effective. And the PBS scheme is a key part of our public health care system and the envy of the world[19].

The Australian government should resist any changes to the regulatory approval processes that come from the US.

References

  1. ^ critics in the United States (www.theguardian.com)
  2. ^ Food and Drug Administration (www.fda.gov)
  3. ^ 150 different pharmaceutical dosage forms (www.fda.gov)
  4. ^ clinical trials (www.australianclinicaltrials.gov.au)
  5. ^ 15 years (patentpc.com)
  6. ^ A$3.5 billion (www.genengnews.com)
  7. ^ 90% of drugs (pmc.ncbi.nlm.nih.gov)
  8. ^ Australian Register of Therapeutic Goods (www.tga.gov.au)
  9. ^ Pharmaceutical Benefits Scheme (www.pbs.gov.au)
  10. ^ 240 to 260 (springbiosolution.com)
  11. ^ 180 to 300 days (synergbiopharma.com)
  12. ^ two weeks (www.tga.gov.au)
  13. ^ three to six times (www.pbs.gov.au)
  14. ^ 32 months (www.theguardian.com)
  15. ^ usually takes (www.pbs.gov.au)
  16. ^ Australia’s PBS means consumers pay less for expensive medicines. Here’s how this system works (theconversation.com)
  17. ^ parallel applications (www.pbs.gov.au)
  18. ^ $17.7 billion (www.pbs.gov.au)
  19. ^ envy of the world (www.medicinesaustralia.com.au)

Read more https://theconversation.com/does-australia-really-take-too-long-to-approve-medicines-as-the-us-says-260910

Jim Chalmers wants roundtable to ‘crack open’ the challenge of slow housing approvals

The Reserve Bank’s rate cut this week will help relieve many mortgage holders, but it wasn’t all positive news...

Times Magazine

DIY Is In: How Aussie Parents Are Redefining Birthday Parties

When planning his daughter’s birthday, Rich opted for a DIY approach, inspired by her love for drawing maps and giving clues. Their weekend tradition of hiding treats at home sparked the idea, and with a pirate ship playground already chosen as t...

When Touchscreens Turn Temperamental: What to Do Before You Panic

When your touchscreen starts acting up, ignoring taps, registering phantom touches, or freezing entirely, it can feel like your entire setup is falling apart. Before you rush to replace the device, it’s worth taking a deep breath and exploring what c...

Why Social Media Marketing Matters for Businesses in Australia

Today social media is a big part of daily life. All over Australia people use Facebook, Instagram, TikTok , LinkedIn and Twitter to stay connected, share updates and find new ideas. For businesses this means a great chance to reach new customers and...

Building an AI-First Culture in Your Company

AI isn't just something to think about anymore - it's becoming part of how we live and work, whether we like it or not. At the office, it definitely helps us move faster. But here's the thing: just using tools like ChatGPT or plugging AI into your wo...

Data Management Isn't Just About Tech—Here’s Why It’s a Human Problem Too

Photo by Kevin Kuby Manuel O. Diaz Jr.We live in a world drowning in data. Every click, swipe, medical scan, and financial transaction generates information, so much that managing it all has become one of the biggest challenges of our digital age. Bu...

Headless CMS in Digital Twins and 3D Product Experiences

Image by freepik As the metaverse becomes more advanced and accessible, it's clear that multiple sectors will use digital twins and 3D product experiences to visualize, connect, and streamline efforts better. A digital twin is a virtual replica of ...

The Times Features

How to Choose a Cosmetic Clinic That Aligns With Your Aesthetic Goals

Clinics that align with your goals prioritise subtlety, safety, and client input Strong results come from experience, not trends or treatment bundles A proper consultation fe...

7 Non-Invasive Options That Can Subtly Enhance Your Features

Non-invasive treatments can refresh your appearance with minimal downtime Options range from anti-wrinkle treatments to advanced skin therapies Many results appear gradually ...

What is creatine? What does the science say about its claims to build muscle and boost brain health?

If you’ve walked down the wellness aisle at your local supermarket recently, or scrolled the latest wellness trends on social media, you’ve likely heard about creatine. Creati...

Whole House Water Filters: Essential or Optional for Australian Homes?

Access to clean, safe water is something most Australians take for granted—but the reality can be more complex. Our country’s unique climate, frequent droughts, and occasional ...

How Businesses Turn Data into Actionable Insights

In today's digital landscape, businesses are drowning in data yet thirsting for meaningful direction. The challenge isn't collecting information—it's knowing how to turn data i...

Why Mobile Allied Therapy Services Are Essential in Post-Hospital Recovery

Mobile allied health services matter more than ever under recent NDIA travel funding cuts. A quiet but critical shift is unfolding in Australia’s healthcare landscape. Mobile all...